Resumen
Definición
Anamnesis y examen
Principales factores de diagnóstico
- presencia de factores de riesgo
- despigmentación de la piel de la zona acral y perioral
- despigmentación de la piel de la zona perianal y genital
- traumatismo cutáneo reciente
- dolor localizado por quemadura solar
- realce y fluorescencia con exposición a radiación UVA
- nevo con halo
- despigmentación universal
Factores de riesgo
- edad <30 años
- antecedentes familiares de vitiligo
- enfermedad autoinmune
- contacto químico
诊断性检查
首要检查
- diagnóstico clínico
需考虑的检查
- Examen con lámpara de Wood
- biopsia de piel
治疗流程
vitiligo segmentario o vitiligo limitado
vitiligo generalizado (más del 3% del área de superficie corporal)
撰稿人
作者
John E. Harris, MD, PhD
Professor
Department of Dermatology
University of Massachusetts Medical School
Worcester
MA
利益声明
JEH has acted as a consultant and/or investigator for: Pfizer, Genzyme/Sanofi, Aclaris Therapeutics Inc., Incyte, Rheos Medicines, Sun Pharmaceuticals, LEO Pharma, Villaris Therapeutics Inc., Dermavant, Temprian, AbbVie Inc., Janssen, TeVido, BioDevices, EMD Serono, Almirall, Boston Pharma, Sonoma Biotherapeutics Inc., Methuselah Health, Twi Biotech, Pandion, Cogen Therapeutics Inc., Admirx, BridgeBio, AnaptysBio, Avita, Frazier Management. He has equity in TeVido Biodevices, Rheos, and Villaris Therapeutics Inc., and is the Scientific Founder of Villaris Therapeutics Inc. JEH is an author of a number of references cited in this topic.
Mehdi Rashighi, MD
Assistant Professor
Department of Dermatology
University of Massachusetts Medical School
Worcester
MA
利益声明
MR has received consulting fees and/or research grants from the following: Pfizer, AbbVie, Dermavant, LEO Pharma, and Almirall. MR is an author of a reference cited in this topic.
鸣谢
Professor John E. Harris and Dr Mehdi Rashighi would like to gratefully acknowledge Dr Bernhard Ortel, a previous contributor to this topic. BO declares that he has no competing interests.
同行评议者
Iltefat Hamzavi, MD
Senior Staff Physician
Multicultural Dermatology Center
Henry Ford Hospital
Detroit
MI
利益声明
IH is an author of a number of references cited in this topic.
Piergiacomo Calzavara-Pinton, MD
Chair
Dermatology Department
University of Brescia
Brescia
Italy
利益声明
PC-P is an author of a number of references cited in this topic.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
参考文献
关键文献
Ortonne J-P. Vitiligo and other disorders of hypopigmentation. In: Bolognia JL, Jorrizzo JL, Rapini RP, eds. Dermatology. New York, NY: Mosby; 2008:913-38.
Taieb A, Picardo M. Clinical practice: vitiligo. N Engl J Med. 2009 Jan 8;360(2):160-9. 摘要
Taieb A, Alomar A, Böhm M, et al; Vitiligo European Task Force (VETF); European Academy of Dermatology and Venereology (EADV); Union Européenne des Médecins Spécialistes (UEMS). Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol. 2013 Jan;168(1):5-19.全文 摘要
Whitton ME, Pinart M, Batchelor J, et al. Interventions for vitiligo. Cochrane Database Syst Rev. 2015 Feb 24;(2):CD003263.全文 摘要
参考文献
A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
鉴别诊断
- Piebaldismo
- Síndrome de Waardenburg
- Esclerosis tuberosa
更多 鉴别诊断指南
- British Association of Dermatologists guidelines for the management of people with vitiligo 2021
- Guidelines for the management of vitiligo
更多 指南
登录或订阅即可浏览 BMJ Best Practice 临床实践完整内容
内容使用需遵循免责声明